Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2019 · on this map
   Pooled it
2. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.Circulation · 2018 · on this map
   Trial
3. Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management.International journal of molecular sciences · 2025
   Review
4. Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases.Pharmaceuticals (Basel, Switzerland) · 2023
   Article
5. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.Drugs · 2015
   Review
6. Associations between pentraxin 3 and severity of coronary artery disease.BMJ open · 2015
   Article
7. Anti-inflammatory therapies for cardiovascular disease.European heart journal · 2014
   Review
8. Relationship of high sensitivity C-reactive protein with presence and severity of coronary artery disease.Pakistan journal of medical sciences · 2013
   Article
9. The evolution or revolution of statin therapy in primary prevention: where do we go from here?Current atherosclerosis reports · 2013
   Review
10. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?Transactions of the American Clinical and Climatological Association · 2013
    Article
11. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?Current atherosclerosis reports · 2013
    Review
12. Rosuvastatin-attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway.Journal of cellular and molecular medicine · 2012
    Article
13. Hyperlipidemia as an instigator of inflammation: inaugurating new approaches to vascular prevention.Journal of the American Heart Association · 2012
    Article
14. Antihyperlipidemic, anti-inflammatory, analgesic, and antipyretic activities of "dimethyl dimethoxy biphenyl dicarboxylate" in male Wistar rats.Journal of advanced pharmaceutical technology & research
    Article

Corrections and comments

• Comment on
  Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as